Ovarian Cancer: Optimizing the Management Based on Mutations and Biomarkers to Direct Treatment with PARP Inhibitors and Immunotherapy – Enduring Webcast

Description

Program Description

---

As epithelial ovarian cancer (OC) treatment moves further into personalized medicine, the importance of determining the inherited mutations in cancer susceptibility genes has grown. Testing for germline mutations in the BRCA1 and BRCA2 genes is becoming routine which are responsible for a significant proportion of OC and are established predictive biomarkers of potential benefit from poly ADP ribose polymerase (PARP) inhibitors. Identifying patients with hereditary OC allows the patient to benefit from personalized treatment while allowing family members to undergo cascade testing, where identification of unaffected carriers can enable early detection, risk-reduction, or prevention for both breast and OC and ultimately improve long-term outcomes.

Intended Audience

---

Medical oncologists, obstetrician-gynecologists, pathologists, nurse practitioners, and physician assistants diagnosing and treating patients with OC

Commercial Supporter

---

This activity is supported by an educational grant from AstraZeneca.